Caloric restriction ameliorates angiotensin II-induced mitochondrial remodeling and cardiac hypertrophy

Hypertension. 2012 Jan;59(1):76-84. doi: 10.1161/HYPERTENSIONAHA.111.179457. Epub 2011 Nov 7.

Abstract

Angiotensin II-induced cardiac damage is associated with oxidative stress-dependent mitochondrial dysfunction. Caloric restriction (CR), a dietary regimen that increases mitochondrial activity and cellular stress resistance, could provide protection. We tested that hypothesis in double transgenic rats harboring human renin and angiotensinogen genes (dTGRs). CR (60% of energy intake for 4 weeks) decreased mortality in dTGRs. CR ameliorated angiotensin II-induced cardiomyocyte hypertrophy, vascular inflammation, cardiac damage and fibrosis, cardiomyocyte apoptosis, and cardiac atrial natriuretic peptide mRNA overexpression. The effects were blood pressure independent and were linked to increased endoplasmic reticulum stress, autophagy, serum adiponectin level, and 5' AMP-activated protein kinase phosphorylation. CR decreased cardiac p38 phosphorylation, nitrotyrosine expression, and serum insulin-like growth factor 1 levels. Mitochondria from dTGR hearts showed clustered mitochondrial patterns, decreased numbers, and volume fractions but increased trans-sectional areas. All of these effects were reduced in CR dTGRs. Mitochondrial proteomic profiling identified 43 dTGR proteins and 42 Sprague-Dawley proteins, of which 29 proteins were in common in response to CR. We identified 7 proteins in CR dTGRs that were not found in control dTGRs. In contrast, 6 mitochondrial proteins were identified from dTGRs that were not detected in any other group. Gene ontology annotations with the Panther protein classification system revealed downregulation of cytoskeletal proteins and enzyme modulators and upregulation of oxidoreductase activity in dTGRs. CR provides powerful, blood pressure-independent, protection against angiotensin II-induced mitochondrial remodeling and cardiac hypertrophy. The findings support the notion of modulating cardiac bioenergetics to ameliorate angiotensin II-induced cardiovascular complications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / metabolism*
  • Angiotensin II / pharmacology
  • Angiotensinogen / genetics
  • Animals
  • Apoptosis / physiology
  • Autophagy / drug effects
  • Autophagy / physiology
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Body Temperature / drug effects
  • Body Temperature / physiology
  • Caloric Restriction / methods*
  • Cardiomegaly / diet therapy*
  • Cardiomegaly / genetics
  • Cardiomegaly / metabolism*
  • Endoplasmic Reticulum Stress / drug effects
  • Endoplasmic Reticulum Stress / physiology
  • Energy Metabolism / drug effects
  • Energy Metabolism / physiology
  • Heart Rate / drug effects
  • Heart Rate / physiology
  • Humans
  • Mitochondria / drug effects
  • Mitochondria / metabolism*
  • Mitochondrial Diseases / metabolism
  • Mitochondrial Diseases / pathology
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Oxidative Stress / drug effects
  • Oxidative Stress / physiology
  • Proteome / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Transgenic
  • Renin / genetics
  • Survival Rate
  • Vasoconstrictor Agents / metabolism
  • Vasoconstrictor Agents / pharmacology

Substances

  • Proteome
  • Vasoconstrictor Agents
  • Angiotensinogen
  • Angiotensin II
  • Renin